Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹786.15 - ₹1,697.00
Previous CloseN/A
Volume67.81K
Average Volume (3M)60.25K
Market Cap
₹296.45B
Enterprise Value₹208.44B
Total Cash (Recent Filing)₹1.58B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)81.3
Beta0.94
Next Earnings
Nov 05, 2026EPS Estimate
3.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.17
Shares Outstanding212,417,860
10 Day Avg. Volume84,130
30 Day Avg. Volume60,249
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,610.00Price Target Upside59.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.81
Revenue Forecast (FY)₹26.19B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Margin GrowthThe sharp FY2026 revenue increase alongside higher net, EBIT, and EBITDA margins indicates strong operating momentum and improving scalability. If sustained, this combination can support reinvestment, strengthen profitability, and improve the company’s ability to serve more complex pharmaceutical programs.
Conservative Balance SheetLow and improving leverage gives SAI Life Sciences financial flexibility to invest in development and manufacturing capacity without relying heavily on debt. A stronger equity base and rising returns on equity also provide a more durable foundation for supporting growth through changing industry conditions.
Integrated CRDMO PlatformSAI Life Sciences’ integrated CRDMO offering can deepen customer relationships by covering multiple stages of the drug lifecycle. Supporting programs from early research through manufacturing may increase repeat work, broaden revenue opportunities, and help customers remain with the company as molecules advance.
Bears Say
Persistent Negative Free Cash FlowDespite improved operating cash generation, persistent negative free cash flow shows that accounting growth is not yet translating into surplus cash. Continued reinvestment or working-capital absorption could increase funding needs and limit the cash available for discretionary investment or balance-sheet strengthening.
Gross Margin PressureThe lower gross margin suggests that input-cost or pricing pressure remains within the delivery of the company’s services. Even with operating leverage improving, sustained gross-margin erosion could constrain future profit expansion and make earnings more dependent on cost control and mix.
Dependence On Program Progression And UtilizationThe business benefits when customer molecules advance and facilities remain well utilized, but revenue and earnings are therefore tied to the flow and progression of contracted programs. Slower project activity or weaker repeat engagements could reduce growth and leave capacity less productive.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹786.15 and its highest was ₹1697.00 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹296.45B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on Aug 06, 2026. The company reported ₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹3.6 by -₹0.1.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate is 3.97.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,417,860 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹3.5 in its last earnings report, missing expectations of ₹3.6. Following the earnings report the stock price went up 1.572%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,610.00
▲(59.37% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―







